AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02285634
Drug: Lidocaine 1% plus epinephrine 1:100,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sterile gauze soaked in 5 milliliters (mL) of Lidocaine 1% plus epinephrine 1:100,000 into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
Trial: NCT02285634
Drug: Bacteriostatic 0.9% NaCL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sterile gauze soaked in 5 milliliters (mL) of Bacteriostatic 0.9% NaCL into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
Trial: NCT00450983
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01514825
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00957619
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group will be treated with saline solution at the same time points. The infusion volume and infusion rate of saline solution correspond to that of the PTF group.
Trial: NCT00384293
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: niacin (+) laropiprant (2 g) placebo po qd.
Trial: NCT00194792
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00194792
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01226537
Drug: Taurine
RxNorm normalized name: Taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg taurine capsules twice per day for 6 months
Trial: NCT00430365
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo
Trial: NCT03553563
Drug: D961H capsule 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All Groups can select either capsule or sachet during the study.
Trial: NCT02568709
Drug: Saline Nasal Spray
RxNorm normalized name: Saline Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 IU of the saline nasal spray will be administered once at the beginning of the visit.
Trial: NCT00303277
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvastatin 40 mg tablets once per day for 12 weeks
Trial: NCT00303277
Drug: pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pravastatin 80 mg tablets once per day for 12 weeks
Trial: NCT02766725
Drug: placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vaginal gel
Trial: NCT00003531
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with Stage IV Pancreatic Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT00338130
Drug: AZD6244
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral liquid or Capsule
Trial: NCT00251316
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients recently diagnosed with papillary or follicular thyroid cancer who have had their thyroid gland removed and whose cancer has not spread beyond the thyroid may be eligible for this study. Participants in this arm receive placebo (look-alike capsules with no active ingredient).
Trial: NCT00346164
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01144403
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: as prescribed, 6 cycles
Trial: NCT00537199
Drug: OraTest
RxNorm normalized name: testosterone enanthate Injectable Solution [Duratest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two (2) scheduled visits for rinse staining: 2 teaspoons of OraTest for 20 seconds, then spit.
Trial: NCT02266849
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 tablets daily for three days
Trial: NCT02624167
Drug: NW-3509A
RxNorm normalized name: DRESSING,HYDRASORB 4IN X 4IN KEN#1694-NW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be given oral doses of 15, 20 and 25 mg BID of NW-3509A
Trial: NCT02624167
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be given oral dose of matching Placebo
Trial: NCT01332786
Drug: Tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage Form: one-hour intravenous infusion Dosage levels, frequency, duration: (3-week cycles)~* Level 1: 50 mg daily x 10 doses; 1 week rest~* Level 2: 100 mg daily x 10 doses; 1 week rest~* Level 3: 150 mg daily x 10 doses; 1 week rest~* Level 4: 200 mg daily x 10 doses 1 week rest~* Level 5: 250 mg daily x 10 doses; 1 week rest~* Level 6: 300 mg daily x 10 doses; 1 week rest~* Level 7: 350 mg daily x 10 doses; 1 week rest
Trial: NCT01443689
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be given conventional therapy only.
Trial: NCT03187496
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each subject will receive caffeine on Days 1 and 12.
Trial: NCT03187496
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Each subject will receive rosuvastatin on Days 2 and 13.
Trial: NCT02170831
Drug: BIBR 1048 MS placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03166124
Drug: LY900014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT01177163
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one placebo capsule once daily for 3 days immediately prior to randomization to double-blind treatment with JNJ 28431754 or placebo
Trial: NCT01177163
Drug: JNJ 28431754 300 mg/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one 300-mg capsule of JNJ-28431754 or placebo twice-daily for 4 weeks
Trial: NCT01177163
Drug: JNJ 28431754 100 mg/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one 100-mg capsule of JNJ-28431754 or placebo once-daily for 4 weeks
Trial: NCT03291041
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule
Trial: NCT00739973
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02498535
Drug: Nitric Oxide 160 ppm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitric Oxide 160 ppm
Trial: NCT02105155
Drug: Conversion at day 7 ± 3 Prograf® to Advagraf®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conversion from Prograf® (tacrolimus administered twice daily) to Advagraf® (once-daily prolonged-release tacrolimus) at day 7±3
Trial: NCT02105155
Drug: Conversion at day 90±5 Prograf® to Advagraf®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conversion from Prograf® (tacrolimus administered twice daily) to Advagraf® (once-daily prolonged-release tacrolimus) at day 90±5
Trial: NCT03492658
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be randomized to treatment with either methotrexate monotherapy (10 - 25 mg once weekly) or a combination therapy of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) in both groups for another 6 months.
Trial: NCT00339872
Drug: IMA-638
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02198924
Drug: Parecoxib and Celecoxib
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Patients in the study group are supplied sequential treatment with Parecoxib 40 mg intravenously (IV) twice daily (Q12h) for the first 3 days post-surgery followed by Celecoxib 200mg orally twice daily (Q12h) up to 6 weeks post-surgery.
Trial: NCT02198924
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control patients are supplied with the corresponding placebo with the same instructions.
Trial: NCT02130778
Drug: Synthetic GLP-1 (1.5 pmol/kg/min) dissolved in 500 ml 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infusion of synthetic GLP-1 (1.5 pmol/kg/min) saline
Trial: NCT02858726
Drug: CR845 0.5 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV medication delivered three times/week
Trial: NCT02858726
Drug: CR845 1 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV medication delivered three times/week
Trial: NCT02858726
Drug: CR845 1.5mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV medication delivered three times/week
Trial: NCT02858726
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV medication delivered three times/week
Trial: NCT01551147
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match ONO-6950 tablets or over-encapsulated Montelukast tablets dosed in a similar manner
Trial: NCT01392326
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator
Trial: NCT00190879
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00233987
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg/kg IV 2 days before transplant.
Trial: NCT03955939
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered according to label instructions.
Trial: NCT00824369
Drug: No drug will be administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drug will be administered.
Trial: NCT02614963
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irritable bowel syndrome patients treated with placebo
Trial: NCT02188082
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00813826
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule, TID
Trial: NCT01007279
Drug: ROSUVASTATIN
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mg before procedure
Trial: NCT02408445
Drug: testosterone cypionate 200mg/ml
RxNorm normalized name: TESTOSTERONE CYPIONATE 200MG/ML INJ (IN OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in this group will be randomized to receive testosterone cypionate 200 mg/ml to be given intramuscularly every 4 weeks for a total of 3 doses.
Trial: NCT00984516
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal Placebo, 100μl administered once prior to wounding
Trial: NCT00984516
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal Placebo, 100μl administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
Trial: NCT03707041
Drug: P218 (1000 mg) Oral Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg P218 (4 x 250 mg capsules)
Trial: NCT03707041
Drug: Placebo Oral Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules matched to the P218 capsules with regard to appearance and taste
Trial: NCT01465282
Drug: CT327 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% CT327 (w/w) ointment
Trial: NCT01465282
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03136406
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Trial: NCT03136406
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Trial: NCT03136406
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
Trial: NCT02644161
Drug: Antidepressant
RxNorm normalized name: Antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will continue their existing antidepressant therapy as usual. Treatment regimens may be further adjusted during 8 weeks of study, depending upon physicians' discretion.
Trial: NCT03404401
Drug: BLI4700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bowel preparation
Trial: NCT00988208
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo once each day on Days 1-14 of the treatment cycle
Trial: NCT01796964
Drug: ESBA1008 solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For intravitreal (IVT) injection
Trial: NCT01757899
Drug: Methylprednisolone Arm
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day 0 - Loading dose 1 mg/kg IV bolus mixed in 5 mL NS (30 min) followed by continuous infusion Days 0 to 07 - 1 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 08 to 10 - 0.5 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 11 to 12 - 0.25 mg/kg/day Days 13 to 14 - 0.125 mg/kg/day
Trial: NCT01757899
Drug: Sterile Saline Arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to the control arm will receive sterile normal saline in an amount that would equal the total diluted dose of study drug (ie. if initial loading dose equals a total of 24 cc \[methylprednisolone + diluting fluid\], then the patient will receive 24 cc of sterile normal saline). Tapering doses will be equivalent to that of the study arm, so that investigators will remain blinded to therapy. The unblinded party will be composed of the research ARDS pharmacist. Five days after the patient is able to ingest medications, placebo is administered per os (PO) in one single daily equivalent dose. The placebo will be manipulated by the pharmacist as to resemble identical to the active drug.
Trial: NCT01546922
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients receive either a low dose HC (0.2-0.3 mg/kg body weight) for 10 weeks followed by 10 weeks of high dose HC (0.4-0.6 mg/kg body weight) or vice versa.
Trial: NCT03170388
Drug: IDP-126 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel
Trial: NCT03170388
Drug: IDP-126 Vehicle Gel
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Gel
Trial: NCT02000531
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (75 mg/m\^2 intravenously \[IV\]) on Day 1 and gemcitabine (1250 mg/m\^2 IV) on Days 1 and 8 of 3-week chemotherapy cycles until disease progression, unacceptable toxicity or up to 4 cycles (whichever comes first)
Trial: NCT02956616
Drug: ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac, sold under the brand name Toradol among others, is a nonsteroidal anti-inflammatory drug in the family of heterocyclic acetic acid derivatives, used as an analgesic. It is considered a first-generation NSAID. Ketorolac acts by inhibiting the bodily synthesis of prostaglandins.
Trial: NCT02227459
Drug: ND-L02-s0201 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00856505
Drug: Everolimus and mycophenolate sodium
RxNorm normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Everolimus tablets, 1.5mg/day bid, dosage adjusted to plasma levels Mycophenolate sodium, 720mg/day bid Duration: Mycophenolate tapering starts at day 56 after stem cell transplantation Everolimus tapering starts at day 100 after stem cell transplantation if no GvHD evident
Trial: NCT03778723
Drug: Total intravenous anesthesia (TIVA)
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1.5-2 mg/kg/h) infusion, Midazolam (0.12 mg/kg/h) infusion
Trial: NCT03778723
Drug: Inhalation Anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevoflurane at a concentration of 2-2.5%
Trial: NCT03778723
Drug: Rescue fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl in repeated doses (50 µg) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value) are used for maintenance of analgesia
Trial: NCT02650141
Drug: ziyinxiehuo Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziyinxiehuo granules Herbs (1 bag ): shengdi 5g, xuanshen 3g, zexie 3g, zhimu3g, huangpai 3g, zhiguiban 2g, maiya 6g,tiandong 3g, zhigancao 2g Therapeutic Principle: Nourishing Yin, removing Fire Usage: administered after dissolved, 3 times per day after breakfast and supper
Trial: NCT02650141
Drug: zishenqinggan Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zishenqinggan granules Herbs (1 bag ): Shengdi 5g, baishao 3g, huangqin 3g, fuling 4g, danpi 3g, maiya 6g, shanzha 3g, zhebei 3g, zhigancao 2g Therapeutic Principle: replenishing Kidney, Clearing Liver Usage: administered after dissolved, 3 times per day after breakfast and supper
Trial: NCT03353298
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo oral tablets given to participants once daily for 9 months
Trial: NCT02274948
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A Placebo tablet physically and chemically similar to Metformin tablets except for the absence of the active ingredient was used
Trial: NCT00031031
Drug: Kanglaite Injection (KLT)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01668121
Drug: Symbicort Turbohaler
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00010413
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02775539
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00314782
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03427476
Drug: CTT1057
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort A: Single IV dose (370 MBq, or 10 mCi). Combined PET/MR or PET/CT imaging (kidney + whole body) will be performed following tracer injection. Patients in cohort A will undergo metastatic lesion biopsy (plus lymph node dissection) within 12 weeks after CTT1057 PET.~Cohort B: Single IV dose (370 MBq, or 10 mCi). Combined PET/MR or PET/CT imaging (kidney + whole body) will be performed following tracer injection. Patients in cohort B (renal cell carcinoma) will have nephrectomy within 12 weeks of CTT1057 PET imaging.
Trial: NCT02640365
Drug: Leucovorin (LV)
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: unresectable metastatic colorectal cancer
Trial: NCT02640365
Drug: 5-fluorouracile (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: unresectable metastatic colorectal cancer
Trial: NCT01975194
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be started at 20 mg per day and then increased to 40 mg per day if not at target by six weeks
Trial: NCT05487560
Drug: Esomezol Cap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomezol Cap, Once daily administered per the locally approved product information
Trial: NCT00003430
Drug: L-778,123
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03417830
Drug: GSK2398852 (unlabeled anti-SAP mAb)
RxNorm normalized name: HURA CREPITANS SAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be administered up to 490 mg of GSK2398852, IV. Dose level will be adjusted based on emerging imaging data.
Trial: NCT03417830
Drug: 89Zr-GSK2398852 (89Zr-labeled anti-SAP mAb)
RxNorm normalized name: HURA CREPITANS SAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 89Zr-GSK2398852 will be available as solution containing 10 mg 89Zr-GSK2398852 for Infusion. Subjects will be administered 37 (Megabecquerel) MBq radioactive dose of 89Zr-GSK2398852 by the IV route at each dosing session.
Trial: NCT00467987
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT04526652
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluating anxiety score in both arms
Trial: NCT03295214
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen given for pain relief
Trial: NCT01825837
Drug: BIA 2-093 300 mg once daily [Group 3 (Part II)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIA 2-093 300 mg taken orally in the evening, for 2 weeks.